WO2018007805A1 - Produits d'hygiène - Google Patents

Produits d'hygiène Download PDF

Info

Publication number
WO2018007805A1
WO2018007805A1 PCT/GB2017/051973 GB2017051973W WO2018007805A1 WO 2018007805 A1 WO2018007805 A1 WO 2018007805A1 GB 2017051973 W GB2017051973 W GB 2017051973W WO 2018007805 A1 WO2018007805 A1 WO 2018007805A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
aqueous antimicrobial
antiviral composition
antimicrobial
amine oxide
Prior art date
Application number
PCT/GB2017/051973
Other languages
English (en)
Inventor
Kumar SIVA
Peter NOWELL
Original Assignee
Biocillin Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocillin Therapeutics Limited filed Critical Biocillin Therapeutics Limited
Publication of WO2018007805A1 publication Critical patent/WO2018007805A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/12—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • Products useful in controlling infectious agents, such as bacteria and viruses are disclosed which are suitable for preparing personal care products and sanitary cleaning products for example.
  • compositions are provided which do not show primary skin irritation potential and / or existing allergic sensitisation.
  • the efficacy of the active substance of this composition which is a QAC
  • the QAC and the surfactant react with one another, reducing the efficacy of the QAC, and therefore the efficacy of the composition, for example a hand-wash or surface spray itself.
  • the anti-microbial activity of the composition can be tested using the European standard chemical disinfectant bactericidal activity EN 1276 test which requires products to demonstrate a bacteria kill rate of 99.999% within 5 minutes.
  • alcohol based hand-washes and sanitisers usually dry after about 7 seconds, after which they cease to be effective.
  • compositions with a pH of at least pH 13.15 are provided.
  • an antimicrobial composition can be diluted in use, for example when used it can be provided in combination with water, for example at a 50% dilution.
  • it may diluted to provide a composition of 25% concentration.
  • the composition further comprises a surfactant.
  • a composition can be provided comprising at least 1 %, suitably in the range 2% to 4% QAC, at least 2%, suitably in the range 2% to 10%, for example 10% Amine oxide and at least 3% surfactant, in particular a non-ionic surfactant or amphoteric surfactant, in particular Lauryl Betaine.
  • a composition can be provided with water in a diluted form, wherein the composition has a pH of at least 1 1 , at least pH 11.5, suitably at least pH 12, suitably at least pH13, suitably at least pH 13.15.
  • An amine oxide may be Ammonyx CSOTM (Ammonyx CSOTM as available from StepanTM Europe). This comprises C12-18 (even numbered) - alkyldimethyl, N- oxides. This differs from, for example, Ammonyx LSOTM (Available from StepanTM) that comprises Lauramine oxide (CM H31 NO) and Dimethyltetradeeylamine oxide. Ammonyx CSOTM may be particularly advantageous.
  • the composition may suitably be provided at a pH greater or equal to pH 1 1 , pH 1 1.5, suitably greater or equal to pH 12, suitably greater or equal to pH 13.
  • a pH of 13.15 or greater, for example pH 13.5 is provided.
  • the aqueous antimicrobial composition has a biocidal activity such that it can kill viruses, suitably, non-enveloped viruses, for example such that it can kill polio virus.
  • the composition may comprise or consist of the following ingredients:
  • Non-ionic surfactant Synperonic 916TM, and / or MEA/ MELA 2% to 8%
  • Alkaline agent potassium carbonate 2% to 8%
  • Chelating agent (CaflonTM EDTA) 2% to 8% pH controller 5% to 10%
  • Demineralised water (q.s. - balance to
  • This composition is referred to as BiocillinTM in the examples provided herein.
  • Such an aqueous antimicrobial composition can be used as an additive to provide antimicrobial activity in a topical formulation for use upon the body. It may be added in an amount of from 20% to 80% (providing an equivalent active concentration of QAC of 1.0% to 4.0% in a finished product (topical formulation).
  • the aqueous antimicrobial composition can be added to other compositions intended for use for personal hygiene purposes or for sanitary purposes e.g. surface cleansers and sanitizers.
  • the use of the disclosed antimicrobial composition is described in topical formulations intended for use upon the human or animal body without limitation.
  • the QAC may be provided at equal or greater than 3%, equal or greater than 4%, equal or greater than 4.5%.
  • Ingredients such as surfactant, humectant, solubiliser and / or fragrance can be used together with from 20.0% to 80.0% of an antimicrobial composition comprising QAC, for example DDAC, prior to addition of the amine oxide suitably Ammonyx CSOTM, such that when the final aqueous solution is made up with a sufficient quantity of water to 100% it provides an active concentration of antimicrobial composition (QAC) in the topical formulation in the range of from 1.0% to 4.0% and at least 5% amine oxide, suitably at least 10 % amine oxide for example Ammonyx CSOTM, suitably 10% to 15%, suitably 10% to 20% Ammonyx CSOTM.
  • QAC active concentration of antimicrobial composition
  • a topical formulation for use on the human hand may comprise the following formulation ingredients:
  • Such ingredients are used together with from 20.0% to 80.0% antimicrobial composition comprising QAC as disclosed herein, for example BiocillinTM
  • composition and made up with a sufficient quantity of water to "100%" to provide an active concentration of antimicrobial composition in the topical formulation with an amine oxide, suitably Ammonyx CSOTM at a concentration of at least 10%.
  • an amine oxide suitably Ammonyx CSOTM at a concentration of at least 10%.
  • At least a second surfactant may be provided, for example, at least a second non-ionic surfactant or amphoteric surfactant.
  • an amphoteric surfactant may be an alkyl betaine for example where the alkyl group is
  • Embodiments of personal care products or hygiene products include an aqueous antimicrobial composition
  • an aqueous antimicrobial composition comprising an antiseptic quaternary ammonium compound (QAC), an amine oxide for example selected from Ammonyx CSOTM and at least one other surfactant in an aqueous vehicle together with additional formulation aids selected from further surfactants, solubilisers, spreading agents, humectants, thickeners, pH regulators, and fragrances or other additives such as those used typically in the field of personal care products.
  • the pH can be suitably regulated to ensure the pH of the aqueous composition or any subsequent diluted solution therefore is alkaline, in particular greater than pH 1 1 , greater than pH 1 1.5, greater than pH 12, greater than pH 13.
  • the QAC may be a long chain alkyl ammonium compound.
  • Didecyl dimethyl ammonium chloride (DDAC) is an example of a quaternary ammonium based antimicrobial agent providing the antiseptic or disinfecting activity required of the disclosed aqueous antimicrobial composition.
  • the aqueous antimicrobial composition disclosed herein may be presented as "concentrate" additive to be diluted with water and combined with formulation components at a point of use or in a separate manufacturing facility to form a product such as a topical formulation or a surface cleanser.
  • the concentrate for such use may consist of the antimicrobial composition (QAC, non-ionic surfactant, alkaline agent, chelating agent and pH controller) in sufficient water to allow metered dispensing of a flowable substantially consistent composition.
  • the amine oxide may be provided to an additive composition comprising the QAC such that it is included in the aqueous antimicrobial composition before dilution and combination with formulation components or added at the final product formulation stage.
  • the amount of QAC may be up to 10% or more by weight with respect to the aqueous antimicrobial composition when the sole disinfecting ingredient is DDAC.
  • DDAC is soluble in water and can be made up in water at differing concentrations. DDAC is obtainable commercially at 50% or 80% by weight in aqueous solution.
  • the amount of QAC may be at least about 4% by weight with respect to the aqueous antimicrobial composition.
  • surfactants may be selected from non-ionic and amphoteric surfactants. At least one surfactant may be selected from alkyl betaines such as a Ci2 Ci4 alkyl betaine, or from alkoxylated fatty alcohols, for example ceto-stearyl (Cie- Cis) alcohol ethoxylated.
  • the base aqueous antimicrobial composition before formulation into product may comprise a non-ionic surfactant such as an alcohol ethoxylate, for example cetostearilic alcohol/ethylene oxide (C16-18 ethoxylate).
  • the composition may include other ingredients such as thickeners, solubilisers, humectants, pH regulators or stabilisers, or buffering aids.
  • aqueous antimicrobial composition may be made up in demineralised water.
  • the presently disclosed aqueous antimicrobial composition requires no alcohol (ethanol) for efficacy. Accordingly in embodiments, the aqueous antimicrobial composition and a formulated product containing the same would be substantially alcohol-free. A residual or negligible amount of alcohol may be found in one or more of the additives, but no alcohol need be specifically added for improving efficacy.
  • the aqueous antimicrobial composition comprising the QAC can be used as a concentrate or additive to be further formulated into a final aqueous product formulation to provide a personal care product.
  • the final aqueous product formulation may comprise from 20% to 80% by weight of the aqueous antimicrobial composition including the QAC.
  • a first aqueous solution providing an antimicrobial composition concentrate or additive comprises:
  • a final topical formulation comprising about 40% (suitably 40.5%) of the following additive
  • Chelating agent (CaflonTM EDTA) 6.0
  • amine oxide (suitably Ammonyx CSOTM for example added at 10%) wherein the amine oxide is provided at a final concentration in the range at least 2 to 6 % amine oxide in use, suitably at least 10% and the formulation is at a pH of at least 1 1 , at least pH 1 1.5, suitably in the range pH 1 1 to 13.5, suitably 1 1.5 to 13.5.
  • a formulation comprising about 90% of the following additive
  • Chelating agent (CaflonTM EDTA)
  • MELA Monoethanoloamine
  • amine oxide in combination with water and amine oxide wherein the amine oxide is provided at a final concentration in the range at least 2 to 6 % amine oxide in use (suitably Ammonyx CSOTM), suitably at least 10% amine oxide and the formulation is at a pH of at least 1 1 , at least pH 1 1.5, suitably in the range pH 11 to 13.5 suitably pH 11.5 to 13.5.
  • Ammonyx CSOTM suitably at least 10% amine oxide
  • the formulation is at a pH of at least 1 1 , at least pH 1 1.5, suitably in the range pH 11 to 13.5 suitably pH 11.5 to 13.5.
  • a personal care product comprising 20.0% to 80% of an aqueous antimicrobial composition comprising of
  • humectant 0.5% - 10.0%
  • Demineralised water (balance to 100%)at least 3%
  • an Aqueous Antimicrobial Composition Additive of the formulation may comprise
  • Antimicrobial composition additive (eg as set out in Ex 1) 20.0% to 80.0%*
  • an aqueous personal care or hygiene product formulation comprises about 40% by weight of the aqueous antimicrobial composition concentrate or additive (as described by Example 1), suitably at least 10% by weight of amine oxide, with the balance being water, optionally at least one secondary surfactant and formulation ingredients.
  • the secondary surfactant may be a C12/C14 alkyl betaine, and the secondary surfactant may be present at about 3% by weight.
  • the antibacterial effect of the formulations can be tested against strains of bacteria, as specified in EN 1276 and EN 1499 and also according to EN 14476 against viral pathogens (Polio Type I).
  • strains of bacteria as specified in EN 1276 and EN 1499 and also according to EN 14476 against viral pathogens (Polio Type I).
  • all percentages mentioned are by weight unless otherwise stated.
  • test product met the requirements (with a 30s contact time) as specified in EN 1276 (5 log reduction) for the test organism.
  • Fragrance 1.00% The above provides an alcohol-free formulation suitable for application to the hand providing an effective way of protecting hands from contact viruses and 99.99% of known bacteria.
  • the antimicrobial additive is formulated in the first instance with an amine oxide present, and the formulation into a topical product is completed by later addition of other ingredients required for the intended complete topical product.
  • Example 4 Method
  • a cold process preparation of a topical formulation for the body is described.
  • a suitable clean vessel is provided for the purpose of mixing, and into the clean vessel is added the following formulation amount of ingredients:
  • Antimicrobial Composition Additive (as per Example.1) Mixing is conducted thoroughly to ensure complete solubility and provide an appropriate aqueous antimicrobial composition solution.
  • Into the clean vessel containing the aqueous antimicrobial composition solution is added the following formulation amount of ingredients, mixing thoroughly to ensure complete solubility after each addition
  • a humectant thereby is prepared an aqueous antimicrobial composition for use as a main batch solution.
  • a second suitable clean vessel is provided for the purpose of mixing to prepare a premix, and into the second clean vessel is added additional formulation components including at least:
  • the thus prepared premix is added to the main batch and mixing is carried out thoroughly to prepare a final batch of the target topical formulation for the body.
  • % of amine oxide provided in the main batch solution is provided such that a final in use concentration of amine oxide of 5%, suitably 10 % is provided.
  • a suitable clean vessel is provided for the purpose of mixing, and into the clean vessel is added the following formulation amount of ingredients:
  • Into the clean vessel containing the aqueous antimicrobial composition solution is added the following formulation amount of ingredients, mixing thoroughly to ensure complete solubility after each addition
  • a primary surfactant A primary surfactant
  • a second suitable clean vessel is provided for the purpose of mixing to prepare a premix, and into the second clean vessel is added additional formulation
  • the thus prepared premix is added to the main batch and mixing is carried out thoroughly to prepare a final batch of the target topical formulation for the hand. Appropriate quality control (QC) tests are carried and the final batch approved for filling into packaging for the product.
  • QC quality control
  • a test to determine whether the composition of the present invention caused primary skin irritation potential and / or existing allergic sensitisation was conducted wherein the product to be tested was applied to the skin of a subject via an occulsive patch at concentration as desired.
  • the product under test was Water 46.50%
  • Non-ionic surfactant (fatty alcohol type*) 4-6
  • composition is not considered to have primary skin irritation potential and / or cause existing allergic sensitisation.
  • Comparative testing of other compositions was undertaken. Comparative test composition 1 (Example 2 of GB2391234)
  • Comparative test composition 2 (Example 11 GB2391234)
  • Comparative test composition 4 (Example 6 of WO02/072748)
  • Butyl Cellosolve (ethylene glycol monobutyl ether) 0.751 %
  • Example 11 of GB2391234 Each of the compositions tested except comparative test composition 2 (Example 11 of GB2391234) passed the anti-bacterial screening. The same compositions were tested for antiviral activity. Only the composition of the present invention demonstrated virus-inactivating activity. The results of such testing are provided by figures 2 and 3 which demonstrate a reduction factor greater than 4 was provided for the present composition.
  • Example 8 Each of the compositions tested except comparative test composition 2 (Example 11 of GB2391234) passed the anti-bacterial screening. The same compositions were tested for antiviral activity. Only the composition of the present invention demonstrated virus-inactivating activity. The results of such testing are provided by figures 2 and 3 which demonstrate a reduction factor greater than 4 was provided for the present composition. Example 8
  • compositions including the Aqueous Antimicrobial Composition Additive of the formulation of Example 1 provided above was undertaken to determine the ability of such compositions to act as an anti-viral composition.
  • Non-ionic surfactant (fatty alcohol type*) 4-6
  • composition did not show reduction at either exposure points and thus failed the test.
  • Composition 057
  • composition comprised 40.50% Aqueous Antimicrobial Composition Additive of the formulation of Example 1 50.50% Water
  • An EN 14476 quantitative assay for the evaluation of virucidal activity against Poliovirus type 1 was conducted where a test suspension of virus was added to a solution comprising the product to be tested and maintained at a controlled temperature for an exposure time of 60s and 120s.
  • composition 058 The composition was able to provide reduction factors of 2.38 at both exposure points and thus failed the test.
  • composition comprised
  • An EN 14476 quantitative assay for the evaluation of virucidal activity against Poliovirus type 1 was conducted where a test suspension of virus was added to a solution comprising the product to be tested and maintained at a controlled temperature for an exposure time of 60s and 120s.
  • Poliovirus type 1 was conducted where a test suspension of virus was added to a solution comprising the product to be tested and maintained at a controlled temperature for an exposure time of 30s and 120s. The composition was able to provide reduction factors of 4.91 and 5.22 and thus passed the test.
  • composition was able to provide a reduction factor of 5.22 and thus passed the test.
  • An EN 14476 quantitative assay for the evaluation of virucidal activity against Poliovirus type 1 was conducted where a test suspension of virus was added to a solution comprising the product to be tested and maintained at a controlled temperature for an exposure time of 120s. The composition was able to provide a reduction factor of 5.22 and thus passed the test.
  • An EN 14476 quantitative assay for the evaluation of virucidal activity against Poliovirus type 1 was conducted where a test suspension of virus was added to a solution comprising the product to be tested and maintained at a controlled temperature for an exposure time of 120s.
  • composition was able to provide a reduction factor of 5.22 and thus passed the test.
  • Poliovirus type 1 was conducted where a test suspension of virus was added to a solution comprising the product to be tested and maintained at a controlled temperature for an exposure time of 300s. The composition was able to provide a reduction factor of 4.22 and thus passed the test.
  • An EN 14476 quantitative assay for the evaluation of virucidal activity against Poliovirus type 1 was conducted where a test suspension of virus was added to a solution comprising the product to be tested and maintained at a controlled temperature for an exposure time of 300s.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)

Abstract

La présente invention concerne une composition antimicrobienne et antivirale aqueuse comprenant un composé d'ammonium quaternaire, un tensioactif non ionique, un agent alcalin, un agent de chélation, un régulateur de pH et au moins 10 % d'oxyde d'amine. L'invention concerne des produits de soins personnels comprenant la composition et l'utilisation de la composition dans la désinfection. Les inventeurs ont créé une composition qui offre des propriétés antivirales, qui peuvent être fournies, même à un pH élevé, sans provoquer de problèmes dermatologiques.
PCT/GB2017/051973 2016-07-05 2017-07-04 Produits d'hygiène WO2018007805A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1611745.9 2016-07-05
GBGB1611745.9A GB201611745D0 (en) 2016-07-05 2016-07-05 Hygiene products

Publications (1)

Publication Number Publication Date
WO2018007805A1 true WO2018007805A1 (fr) 2018-01-11

Family

ID=56891124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2017/051973 WO2018007805A1 (fr) 2016-07-05 2017-07-04 Produits d'hygiène

Country Status (2)

Country Link
GB (2) GB201611745D0 (fr)
WO (1) WO2018007805A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111596A1 (fr) * 2021-12-17 2023-06-22 Gama Healthcare Limited Lingette humide désinfectante
WO2023225253A1 (fr) * 2022-05-20 2023-11-23 The Procter & Gamble Company Procédés de potentialisation d'un biocide

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023087195A1 (fr) * 2021-11-18 2023-05-25 Ecolab Usa Inc. Compositions de nettoyage et de désinfection à usages multiples à séchage rapide et leurs procédés d'utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476615A (en) * 1994-05-20 1995-12-19 Lonza Inc. Low foam sanitizers
WO2002072748A1 (fr) * 2001-03-13 2002-09-19 S.C. Johnson & Son, Inc. Nettoyant antimicrobien pour surface dure a effet antimicrobien residuel
GB2391234A (en) * 2002-07-24 2004-02-04 Reckitt Benckiser Inc Hard surface cleaning compositions
WO2012080918A2 (fr) * 2010-12-14 2012-06-21 Ecolab Usa Inc. Compositions antimicrobiennes résistantes à l'usure et procédés d'utilisation
US20150148425A1 (en) * 2013-11-25 2015-05-28 The Dial Corporation Antimicrobial composition exhibiting increased efficacy
WO2015148063A1 (fr) * 2014-03-25 2015-10-01 Ecolab Usa Inc. Compositions antimicrobiennes contenant des ingrédients actifs cationiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012255121A (ja) * 2011-06-10 2012-12-27 Niitaka:Kk 濃縮液体洗剤、パウチ入り濃縮液体洗剤及び被洗浄物の洗浄方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476615A (en) * 1994-05-20 1995-12-19 Lonza Inc. Low foam sanitizers
WO2002072748A1 (fr) * 2001-03-13 2002-09-19 S.C. Johnson & Son, Inc. Nettoyant antimicrobien pour surface dure a effet antimicrobien residuel
GB2391234A (en) * 2002-07-24 2004-02-04 Reckitt Benckiser Inc Hard surface cleaning compositions
WO2012080918A2 (fr) * 2010-12-14 2012-06-21 Ecolab Usa Inc. Compositions antimicrobiennes résistantes à l'usure et procédés d'utilisation
US20150148425A1 (en) * 2013-11-25 2015-05-28 The Dial Corporation Antimicrobial composition exhibiting increased efficacy
WO2015148063A1 (fr) * 2014-03-25 2015-10-01 Ecolab Usa Inc. Compositions antimicrobiennes contenant des ingrédients actifs cationiques

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111596A1 (fr) * 2021-12-17 2023-06-22 Gama Healthcare Limited Lingette humide désinfectante
WO2023111595A1 (fr) * 2021-12-17 2023-06-22 Gama Healthcare Limited Formulation universelle
WO2023225253A1 (fr) * 2022-05-20 2023-11-23 The Procter & Gamble Company Procédés de potentialisation d'un biocide

Also Published As

Publication number Publication date
GB201611745D0 (en) 2016-08-17
GB201710763D0 (en) 2017-08-16
GB2552261A (en) 2018-01-17

Similar Documents

Publication Publication Date Title
JP6154935B2 (ja) カチオン性活性成分および第四級糖から誘導された界面活性剤を含む抗菌性組成物
CN109414026A (zh) 用于为硬表面清洁和杀菌的无痕耐久型组合物
US20090035339A1 (en) Methods of Inactivating Viruses
CA2697249C (fr) Compostions antimicrobiennes
US5122541A (en) Sprayable surface disinfectant
WO2009093476A1 (fr) Composition de nettoyant antibactérien pour siège de toilettes, produit de nettoyage antibactérien la comprenant et procédé de nettoyage antibactérien utilisant la composition ou le produit
CN109561694A (zh) 抗微生物组合物
JP5162191B2 (ja) 皮膚外用剤
CN103501606B (zh) 用于中链脂肪酸的偶联剂和灭菌组合物
WO2018007805A1 (fr) Produits d'hygiène
US11871749B2 (en) Alcohol-free hydrogen peroxide disinfectant compositions and methods of use thereof
EP1876225A1 (fr) composition désinfectante douce pour la peau et à large spectre
JP6704099B1 (ja) 殺菌またはウイルス不活性化剤組成物、および殺菌またはウイルス不活性化効力増強方法
DE1642056A1 (de) Antimikrobielle Mittel
EP3389377A1 (fr) Compositions alcooliques à teneur en dichlorhydrate d'octénidine
JP2023038372A (ja) 殺菌剤組成物
WO2011015881A2 (fr) Composition biocide
JP7340290B2 (ja) 抗エンベロープウイルス中性洗浄剤、消毒剤組成物、及びエンベロープウイルスの不活性化方法
RU2230574C1 (ru) Средство дезинфицирующее
US20200267973A1 (en) Alkaline disinfecting compositions
RU2366175C1 (ru) Дезинфицирующее средство
WO2022244531A1 (fr) Détergent neutre anti-virus enveloppé, composition désinfectante et procédé d'inactivation de virus enveloppés
WO2023145560A1 (fr) Composition pour inactiver un virus ou une bactérie
CA3215893A1 (fr) Desinfectant et son utilisation
WO2023145559A1 (fr) Procédé d'inactivation de virus ou de bactérie

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17739653

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08.04.2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17739653

Country of ref document: EP

Kind code of ref document: A1